Loading stock data…
Loading stock data…
US$10.97
Get one email when PHAT crosses your level. Checked every 15 minutes during market hours.
▼ -0.08 (-0.72%)down today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
48.5
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
0.14
Bearish momentumMACD below its signal line (0.15).
50-day average
11.08
Price belowShort-term trend reference.
200-day average
12.70
Price belowLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Phathom Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases related to acid. Its flagship product, VOQUEZNA (vonoprazan), a potassium-competitive acid blocker, is approved for adults with erosive gastroesophageal reflux disease (GERD) and heartburn, as well as non-erosive GERD. The company also offers VOQUEZNA Triple Pak and VOQUEZNA Dual Pak combination therapies for treating Helicobacter pylori infections.…
www.phathompharma.com6 strong buy · 9 buy · 2 hold · 0 sell · 0 strong sell (17 analysts, 2026-07-01)
6 strong buy · 9 buy · 2 hold · 0 sell · 0 strong sell (17 analysts, 2026-06-01)
6 strong buy · 9 buy · 2 hold · 0 sell · 0 strong sell (17 analysts, 2026-05-01)
6 strong buy · 9 buy · 2 hold · 0 sell · 0 strong sell (17 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-04-30 | -0.19 | -0.18 | ✓ Beat |
| 2026-02-26 | -0.19 | -0.08 | ✓ Beat |
| 2025-10-30 | -0.41 | -0.15 | ✓ Beat |
| 2025-10-14 | 0.45 | 0.51 | ✓ Beat |
| 2025-09-23 | 1.23 | 2.36 | ✓ Beat |
| 2025-08-07 | -0.92 | -0.79 | ✓ Beat |
| 2025-05-01 | -1.07 | -1.07 | ✓ Beat |
Companies in the same industry, via Finnhub